A UK trial swapped standard chemotherapy for a short course of pembrolizumab, and none of the 32 patients has relapsed.

In this extended follow-up from the phase 3 KEYNOTE-826 trial, researchers reported on 5-year outcomes of pembrolizumab and chemotherapy in cervical cancer.

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free ...

As of the data cutoff on August 20, 2026, the median follow-up was 36 months, and a total of 234 overall survival (OS) events had occurred. For this OS analysis, a prespecified O'Brien-Fleming ...

Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with ...

A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility. The European Medicines Agency’s (EMA’s) ...

Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin ...

Ivonescimab topped pembrolizumab alone or paired with chemotherapy in separate trials ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant pembrolizumab plus belzutifan significantly improved DFS compared with pembrolizumab monotherapy in ...

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD ...

On 3, 2026, InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, announced a strategic partnership and ...